Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach-Reference-Cited by-同舟云学术

Clinical Pharmacology Tools and Evaluations to Facilitate Comprehensive Dose Finding in Oncology: A Continuous Risk-Benefit Approach

Published:2017-09-15 Issue: Volume:57 Page:S105-S115
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Bullock Julie M.¹,Lin Tiffany¹,Bilic Sanela¹

Affiliation:

1. D3 Medicine; a Certara USA Company; Parsippany NJ USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference56 articles.

1. Lessons learned: dose selection of small molecule-targeted oncology drugs;Bullock;Clin Cancer Res,2016

2. Dose finding of small-molecule oncology drugs: optimization throughout the development life cycle;Janne;Clin Cancer Res,2016

3. A survey of new oncology drug approvals in the USA from 2010 to 2015: a focus on optimal dose and related postmarketing activities;Lu;Cancer Chemother Pharmacol,2016

4. The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients;Hochhaus;J Cancer Res Clin Oncol,2013

5. Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a phase III study;Wang;Clin Pharmacol Adv Applic,2013

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Multidisciplinary Approach for Liver Cancer;Liver Cancer - Multidisciplinary Approach;2024-07-23

2. A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development;Journal of Pharmacokinetics and Pharmacodynamics;2023-03-04

3. Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors;Investigational New Drugs;2022-08-06

4. Exposure–response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial: support for dosage recommendations;Cancer Chemotherapy and Pharmacology;2022-06-30

5. Dual-Targeting and Stimuli-Triggered Liposomal Drug Delivery in Cancer Treatment;ACS Pharmacology & Translational Science;2021-06-01